WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s

WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s

UTRECHT, The Netherlands, Nov. 07, 2024 (GLOBE NEWSWIRE) — Today, ATNi launches the 5th edition of the Global Access to Nutrition Index, the largest yet, assessing the world’s 30 largest food and beverage manufacturers and over 52,000 products, representing 23% global

Leading Swiss law firm adopts scalable, intuitive solution to strengthen IP management capabilities BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property (IP) management technology, today announced that MLL Legal, one of Switzerland’s largest

REGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating Results FDA approval on track for first quarter 2025, U.S. commercial team build out in progress Company fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of